Glycotex, Inc., a clinical stage biopharmaceutical company, announced that it has been awarded a cash grant totalling $244,479 under the US Government's Qualifying Therapeutic Discovery Project (QTDP) programme. The QTDP programme was created by Congress as part of the Patient Protection and Affordable Care Act of 2010. The company received the grant for its program to develop GLYC-101 Gel investigational product for the treatment of acute and chronic wounds.
GLYC-101 is being developed to stimulate and modulate the natural cascade of wound healing activities of several cell populations. The product candidate is a topical gel to be applied directly on the wound surface.
The strategic priorities for GLYC-101 include wound healing following laser ablation, burn wounds, surgical wounds, venous ulcers, and diabetic ulcers.
Glycotex, Inc. is a US based development stage biopharmaceutical company focused on discovering and developing therapies intended to accelerate human wound healing and tissue repair across a wide range of human applications.